Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Neutral

B

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)

Pharmaceutical Preparations

https://www.moonlaketx.com

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

DORFSTRASSE 29
ZUG, V8

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/06/2022

Market Cap

2,977,146,324

Shares Outstanding

59,940,000

Weighted SO

59,940,529

Total Employees

N/A

Upcoming Earnings

08/08/2024

Beta

1.2500

Last Div

0.0000

Range

35.11-64.98

Chg

-0.7000

Avg Vol

363196

Mkt Cap

2977146324

Exch

NASDAQ

Country

CH

Phone

41 415108022

DCF Diff

38.5207

DCF

9.1093

Div Yield

0.0000

P/S

150833.2315

EV Multiple

-33.6670

P/FV

5.7167

Div Yield %

0.0000

P/E

-54.3117

PEG

-0.8128

Payout

0.0000

Current Ratio

43.7130

Quick Ratio

43.7130

Cash Ratio

27.9101

DSO

31008.0426

DIO

0.0000

Op Cycle

31008.0426

DPO

0.0000

CCC

31008.0426

Gross Margin

-1.9134

Op Margin

-3972.2527

Pretax Margin

-2939.4485

Net Margin

-2776.5626

Eff Tax Rate

-0.0038

ROA

-0.1006

ROE

-0.1105

ROCE

-0.1472

NI/EBT

0.9446

EBT/EBIT

0.7400

EBIT/Rev

-3972.2527

Debt Ratio

0.0061

D/E

0.0064

LT Debt/Cap

0.0039

Total Debt/Cap

0.0064

Int Coverage

-19.9111

CF/Debt

-19.2684

Equity Multi

1.0465

Rec Turnover

0.0118

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0051

Asset Turnover

0.0000

OCF/Share

-1.0248

FCF/Share

-1.0327

Cash/Share

8.2672

OCF/Sales

-3264.4488

FCF/OCF

1.0077

CF Coverage

-19.2684

ST Coverage

-48.7496

CapEx Coverage

-129.8022

Div&CapEx Cov

-129.8022

P/BV

5.7167

P/B

5.7167

P/S

150833.2315

P/E

-54.3117

P/FCF

-45.8516

P/OCF

-46.1946

P/CF

-46.1946

PEG

-0.8128

P/S

150833.2315

EV Multiple

-33.6670

P/FV

5.7167

DPS

0.0000

Latest Headlines (EST)

MarketWatch Dec 28, 09:40 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 28, 09:40 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 28, 04:52 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 27, 14:46 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 27, 14:46 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 Benzinga Nov 07, 14:00 16 Analysts Have This to Say About MoonLake GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis GlobeNewswire Inc. Nov 05, 11:00 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

Revenue Product Segmentation